3 The Availability of Molecular Profiling Results at New Patient Review in NSCLC and the Impact on Patient Care
Optimal systemic anti-cancer therapy (SACT) for non-small cell lung cancer (NSCLC) is dependent on the results of molecular profiling to direct precision medicine. Delays in the availability of results in the clinic can delay care. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Matt Church, Mathew Carter, Yvonne Summers, Fabio Gomes, Paul Taylor, Sarah Hughes, Raffaele Califano, Fiona Blackhall, Colin Lindsay, Laura Cove-Smith Tags: Basic Science Source Type: research
4 Clinical and molecular characteristics of BRAF mutant Lung Adenocarcinomas
We present our experience with BRAF mutant LAC. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Ramesh Bulusu, Ramesh Bulusu, Huiqi Yang, Daniel Patterson, Kamalram Thippu Jayaprakash, Adam McGeogh, Margaret Hutka, Abigail Hollingdale, Sarah Treece, Nicola Thompson, Philip Earwaker, Diedre Lynskey, Shahzeena Aslam, Anna Marie Shiarli Tags: Basic Science Source Type: research
5 Molecular marker expression in non-small cell lung cancer (NSCLC) in Humberside
We evaluated the molecular marker expression in NSCLC patients treated at the Hull University Teaching Hospitals (HUTH) NHS Trust, covering Hull, East Riding, North and East Yorkshire, North and North East Lincolnshire to provide information of local distribution of molecular markers. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Eline Roejkjaer, Azeem Saleem Tags: Basic Science Source Type: research
6 Molecular testing turn around time in NSCLC before and after NGS commissioning in Milton Keynes University Hospital- An Audit 2022 –2023
Lung cancer is most common malignancy, with non-small cell lung cancer (NSCLC) the predominant subtype. Lung cancer accounts for more than 18% cancer related deaths (1). We aim to reflect on our practice of molecular testing on NSCLC, along with PD-L1 expression in 2022 –2023 (before and after NGS commissioning) which will define the choice of treatment, based on the expression of this ligand (immunotherapy alone vs chemotherapy plus immunotherapy). (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Faiza Saleem, Hany Eldeeb, Moyna Dawyer, Syed Azhar Javed Rizvi Tags: Basic Science Source Type: research
7 Concordance of MET amplification detection between FISH and NGS in NSCLC
The INSIGHT-2 trial validated MET amplification as a therapeutic drug target for combination tepotinib-osimertinib in EGFR-mutated NSCLC. Its detection has traditionally relied on fluorescence in situ hybridization (FISH), but this is a separate test to next generation sequencing (NGS), with additional costs. We evaluated the relationship of MET copy number status detected by FISH or NGS to determine if FISH can be abandoned in the diagnostic workup. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Alexius John, Thanika Ketpueak, Suzanne MacMahon, Marianne Wall, Lina Yuan, Nadza Tokaca, Jaishree Bhosle, Anna Minchom, Michael Davidson, Mary O'Brien, David McMahon, Maria Rodriguez Nevado, Sanjay Popat Tags: Basic Science Source Type: research
8 Audit of a 3-day turnaround time for histopathology reporting in lung cancer cases
The NHS England National Optimal Lung Cancer Pathway (NOLCP) is designed to improve outcomes in lung cancer by reducing delays in diagnosis. According to this document, in cases of suspected lung cancer where the pathological diagnosis will influence treatment and management, then there should be histopathology result with subtype available within 3 working days and biomarkers (molecular markers) in 10 working days. In this audit we compare the turnaround times (TAT) in our centre against the desired standard set out by NOLCP. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Rachael Winstanley Tags: Basic Science Source Type: research
9 Lung cancer physician grading of radiology alerted chest x-rays to optimise diagnostic pathways in a resource limited setting
Optimising lung cancer diagnostic pathways, reduces upstaging and benefits 5-year survival. Resource-limited settings may have difficulty attaining 62-day or National Optimal Lung Cancer Pathway targets. One stop, hot-reported CT/physician clinics provide an opportunity to consolidate appointments, but are resource intensive, therefore not practical for all abnormal chest x-rays (CXRs). Aim: We propose a methodology, using lung cancer physician grading of radiology flagged CXRs to allocate ring-fenced weekly slots on a risk-stratified basis. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Katrina Dean, Paul O'Donnell, Rehan Naseer Tags: Clinical Networks and Pathways Source Type: research
10 Current challenges and delays in the lung cancer diagnostic pathway
National Optimal Lung Cancer Pathway (NOLCP) aims to achieve diagnosis or exclusion of lung cancer within 28 days1 from GP referral or abnormal imaging. The first investigation, usually CT thorax, should be performed within 72 hours. A diagnostic “bundle” follows in which delays could occur. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Andrew Fowell, Phebe Bhaskar, Michael Mulrooney, Haider Al-Najjar Tags: Clinical Networks and Pathways Source Type: research
11 Making an accurate diagnosis of anterior mediastinal lesions: A proposal for a new diagnostic algorithm from the BTOG Thymic Interest Group
Due to rising demand in cross-sectional thoracic imaging, anterior mediastinal lesions are being identified with increasing frequency. Following iterative and multidisciplinary discussions, the BTOG Thymic Interest Group have developed an algorithm (Figure 1) to standardise the diagnostic approach for these relatively uncommon but important conditions which span from benign (thymic remnant, thymic hyperplasia and thymic cysts) to low grade malignancy (thymoma) to high grade malignancy (thymic carcinoma, lymphoma and germ cell tumours). (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Stephen Robinson, Matthew Evison, Shalini Datta, Anna Sharman, Kandadai Rammohan, Rebecca Duerden, David Gilligan Tags: Clinical Networks and Pathways Source Type: research
12 Understanding reasons for deviation from lung cancer multidisciplinary team meeting (MDM) recommendations – an audit in a large NHS Foundation Trust
We present data from University Hospitals Birmingham (UHB) NHS Trust (comprising four hospitals). (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Kay Por Yip, Gibril Wardere, Bhavani Adizie, Patricia Glynn Tags: Clinical Networks and Pathways Source Type: research
13 Survey of patients undergoing procedures in a suspected lung cancer and pleural service
Access to diagnostic procedures is instrumental in the faster diagnostic framework and the national optimal lung cancer pathway (NOLCP). We undertook a service evaluation of patient experiences. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Ben Probyn, Gareth Trevelyan, Timothy Howell, Aparna Iyer, Thomas Nicholson, Lindsey Taylor, David Waine, John Corcoran, Cyrus Daneshvar Tags: Clinical Networks and Pathways Source Type: research
14 Widening access and addressing inequalities for patients with lung cancer consenting to systemic anti-cancer therapies (SACT)
Cancer services nationally are under increasing pressure. With new and rapidly emerging therapy lines the consent process for SACT is becoming more complex. Moreover our patient population is more diverse. Research has shown that language services and visual guides can improve patient experience, adherence to treatment and overall health outcomes. We are developing a multi-lingual digital library of animations to support the consent process for SACT with the aim to reduce inequalities in cancer care. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Elizabeth Nally, Annie Reeves, Anna Lerner, Angshu Bhowmik, Pauline Leonard, Oliver Hawkins, David Wald, Adam Januszewski Tags: Clinical Networks and Pathways Source Type: research
15 The Integration and Analysis of Data using Artificial Intelligence to Improve Patient Outcomes with Thoracic Diseases (DART) research programme.
DART is a multi-centre multi-collaborator research programme aiming to improve multiple facets of Lung Cancer Screening (LCS) and provide a very large data set for future research into early lung cancer detection and prognosis. It collects all the clinical metadata, CT scans and PET-CT scans, and pathology from participants both screened and invited to participate in NHS England's Targeted Lung Health Checks (TLHC) screening programme. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Fergus Gleeson Tags: Clinical Networks and Pathways Source Type: research
16 The impact of implanting ctDNA testing on day 0 of the lung cancer pathway in patients with advanced stage disease in Manchester
Circulating tumour DNA (ctDNA) can be detected in peripheral blood of cancer patients and tested for genomic alterations and could support the delivery of the Lung Cancer Optimal Pathway (LCOP). (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Avik Ghoshal, Patrick Goodley, Gaurav Ahuja, Heshani De Silva, Alaa Alsaaty, Charlotte Watson, Richard Booton, Haval Balata, Phil Crosbie, Nicola Sinnott, Jonathan Hiu Nian Chung, Christopher Craig, Matthew Krebs, Anthony Sutcliffe, Matthew Evison Tags: Clinical Networks and Pathways Source Type: research
17 A third treatment pathway: is there a place for a nurse-led Best Supportive Care service for the management of patients diagnosed with lung cancer at an acute NHS Trust?
Cheng et al (2021) identified that patient choice accounted for 56% of BSC decisions in patients who presented as outpatients and 51.3% of those patients managed by BSC were PS 0 –2, highlighting the need for a follow-up service. Following review of this data, the lung cancer CNS team at the UHNM proposed and developed a third treatment arm, running alongside surgery and oncology. This included the implementation of a Best Supportive Care pathway, a standardised electronic assessment tool, and piloting a nurse-led clinic to provide assessment and on-going support. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Laura Fox-Hewitt Tags: Clinical Networks and Pathways Source Type: research
